These findings indicate that only patients with colon cancer (but not those with rectal cancer) treated with adjuvant 5FU could be stratified into better or worse OS prognostic subgroups by TS and E2F1 expression. This evidence concerns the gene E2F1 and malignant colon neoplasm.